Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Monotherapy Of Metastatic Breast Cancer: A Review Of Newer Agents.

C. Vogel, J. Nabholtz
Published 1999 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the response rates of these agents with an emphasis on recent findings, such as presentations from the 1998 Meeting of the American Society of Clinical Oncology. METHODS The English medical literature was reviewed to identify clinical trials involving monotherapy for the treatment of metastatic breast cancer. Three agents--paclitaxel, vinorelbine, and docetaxel--are emphasized because their databases are extensive enough to allow interesting comparisons. Liposomal-encapsulated anthracyclines, losoxantrone, gemcitabine, oral surrogates of continuous-infusion fluorouracil, raltitrexed, LY 231514, edatrexate, topoisomerase I inhibitors, and trastuzumab are reviewed briefly. RESULTS Many of the new agents produce response rates approaching or even surpassing those achievable with doxorubicin monotherapy. Compared with older agents, some new agents have improved or at least different safety profiles, and some are easier to administer. DISCUSSION AND CONCLUSIONS The new agents offer useful therapeutic options that make them suitable for combining with each other and with older agents, which could result in more effective regimens for metastatic disease, and, ultimately, primary disease in the adjuvant setting. The chemotherapeutic paradigms governing the management of breast cancer for the past three decades are likely to change as we move into the 21st century.
This paper references
A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
G. Schwartsmann (1997)
The safety of IV Navelbine® in elderly patients with advanced breast cancer (ABC)
CL Vogel (1994)
10.1093/JNCI/85.4.271
The current status of camptothecin analogues as antitumor agents.
W. Slichenmyer (1993)
Multicenter pilot study of Taxotere in taxol-resistant metastatic breast cancer (MBC)
V Valero (1996)
10.1200/JCO.1995.13.5.1152
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
A. Seidman (1995)
Weekly epirubicin (EPI) and vinorelbine (VNR) plus G-CSF in metastatic breast cancer (MBC): high activity with a 75% survival rate at two years
C Nisticò (1997)
A phase II study of DUP 941 in advanced breast cancer (CA) patients with no prior chemotherapy
T Vandenberg (1993)
Tumor selectivity of XelodaTMin colorectal cancer patients
J Schüller (1997)
10.1200/JCO.1996.14.2.422
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
M. Trudeau (1996)
Docetaxel (D) in combination with vinorelbine (V) as 1st line CT in PTS with metastatic breast cancer (MBC): final results
P Fumoleau (1996)
10.1200/JCO.1993.11.10.1943
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
B. Reichman (1993)
Evolving concepts in the systemic adjuvant treatment of breast cancer.
G. Bonadonna (1992)
10.1200/JCO.1994.12.1.5
High-dose therapy: here to stay or just visiting?
G. Canellos (1994)
A Safety Review of Pegylated Liposomal Doxorubicin in the Treatment of Various Malignancies
D. Alberts (1997)
Clinical drug development: an analysis of phase II trials, 1970-1985.
S. Marsoni (1987)
Prospective randomized study comparing mitoxantrone (M) and vinorelbine (V) with fluorouracil (F), epirubicin (E) or Adriamycin® (A) and cyclophosphamide (C) in patients with metastatic breast cancer
M Namer (1997)
10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
F. Sirotnak (1987)
10.1016/S0959-8049(05)80426-5
Oral tegafur in the treatment of metastatic breast cancer: a phase II study.
M. Kajanti (1993)
A randomized phase II study of XelodaTM (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
SM O’Reilly (1998)
Phase II trial of cisplatin (Cddp) and gemcitabine (dfdc) in heavily pretreated breast cancer
RA Nagourney (1998)
Phase-II study of Navelbine in advanced breast cancer.
L. Canobbio (1989)
A multicenter phase II trial of XelodaTM (capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC)
JL Blum (1998)
Phase II study of IV Navelbine® (NVB) and doxorubicin (DOX) in previously untreated advanced breast cancer (ABC)
D Vorobiof (1997)
10.1093/OXFORDJOURNALS.JJCO.A039662
Phase II trial of UFT activity in pretreated breast cancer patients.
M. Daniels (1993)
10.1200/JCO.1995.13.10.2567
Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.
S. Jones (1995)
Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
C. Brambilla (1986)
10.1136/bmj.1.5901.218
Cyclical Combination Chemotherapy for Advanced Breast Carcinoma
G. Canellos (1974)
A US multicenter phase II study of IV Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC)
CL Vogel (1995)
10.1023/A:1008374425246
Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
M. Martín (2000)
10.1038/bjc.1994.435
A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.
C. Twelves (1994)
10.1002/1097-0142(19890815)64:4<793::AID-CNCR2820640404>3.0.CO;2-8
5‐fluorouracil rechallenge by protracted infusion in refractory breast cancer
K. Jabboury (1989)
10.1200/JCO.1994.12.10.2102
Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
C. Toussaint (1994)
10.1093/OXFORDJOURNALS.ANNONC.A010544
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
P. Fumoleau (1996)
A reappraisal of optimal delivery in advanced breast cancer
NR Anderson (1993)
10.1097/00000421-198910000-00019
Continuous Intravenous Infusion of 5‐Fluorouracil in the Treatment of Refractory Breast Cancer
A. Chang (1989)
A randomized phase II study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged ≥55 years
J O’Shaughnessy (1998)
Tegafur+uracil (UFT)-doxorubicin-cyclophosphamide vs 5FU-doxorubicincyclophosphamide in advanced breast cancer: a randomized trial
AH Villalon (1996)
Doxorubicin and paclitaxel (sequential combination) in the treatment of breast cancer
D Amadori (1997)
10.1200/JCO.1997.15.10.3185
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
10.1200/JCO.1996.14.10.2713
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
F. Holmes (1996)
10.1007/978-3-642-81565-2_28
Recent advances in chemotherapy for advanced breast cancer.
T. Wada (1981)
10.1093/OXFORDJOURNALS.ANNONC.A058903
Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
J. Verweij (1994)
Doxil ® in metastatic breast cancer ( MBC ) after prior chemotherapy : therapeutic results in two consecutive studies
O Lyass (1998)
Infusional chemotherapy for breast cancer
J 184Lokich (1993)
10.1200/JCO.1995.13.11.2731
Advanced breast cancer: a phase II trial with gemcitabine.
J. Carmichael (1995)
Taxotere (TXT) vs vinorelbine and taxol (VIN-TAX) in patients (PTS) with metastatic breast cancer (MBC) anthracycline resistance
HG Botto (1998)
10.1200/JCO.1983.1.2.107
Phase I-II studies of oral tegafur (ftorafur).
F. Ansfield (1983)
10.1200/JCO.1987.5.2.178
High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study.
G. Hortobagyi (1987)
10.1016/S0169-5002(00)80202-0
Phase I study of weekly docetaxel in patients with advanced refractory cancer
M. Takada (2000)
Docetaxel (RP56976) in advanced or recurrent breast cancer: early and late phase II clinical studies in Japan
T Taguchi (1994)
Multicentric phase II study with vinorelbine ( VNB ) and epirubicin ( EPI ) as first line chemotherapy in metastatic breast cancer ( MBC ) . Preliminary data
D Tabiadon (1998)
A phase II trial of docetaxel and gemcitabine as second line treatment in metastatic breast cancer
D Mavroudis (1998)
A phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/recurrent breast cancer (MBC). a National Cancer Institute of Canada study
B Norris (1996)
Doxetaxel + vinorelbine is an active combination for patients with anthracycline-refractory metastatic breast cancer. Results of a phase II trial
P Escudero (1998)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1002/1097-0142(19950201)75:3<831::AID-CNCR2820750314>3.0.CO;2-S
Phase II trial of an all‐oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer
L. Solé (1995)
a first line therapy in patients with metastatic breast cancer (MBC)
JF Bishop (1996)
Modulation of the antitumor activity of ftorafur (Ft) and uracil (U)-Ft combination (UFt) in rats bearing advanced colon carcinoma
S Cao (1993)
10.1016/S0960-9776(97)90117-X
P953. Phase II study of taxotere® (Docetaxel, D), Doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
J. Nabholtz (1997)
Different interference of paclitaxel (PTX) on human pharmacokinetics of doxorubicin (DOX) and epirubicin (EPI)
L Gianni (1997)
10.1200/JCO.1996.14.1.58
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
C. Hudis (1996)
Cytokinetics and breast cancer chemotherapy
T Gilewski (1996)
A clinical trial of intravenous (IV) Navelbine (NVB) (vinorelbine tartrate) for first line treatment of women ≥60 years of age with advanced breast cancer (ABC)
C Vogel (1996)
Experience with UFT in Japan.
T. Taguchi (1997)
High-dose paclitaxel in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Centre trial
J Vermorken (1995)
Final results: randomized Phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pts) with met breast cancer
FA Holmes (1998)
10.1016/0277-5379(89)90259-9
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.
J. Robertson (1989)
Activity of Taxol® (T) by weekly 1 hour infusion in patients (pts) with metastatic breast cancer (MBC): a phase II and pharmacologic study
AD Seidman (1997)
Phase II study of MTA (LY231514) in patients (pts) with locally recurrent or metastatic breast cancer (LR/MBC)
MJ Lind (1998)
10.1200/JCO.1998.16.2.800
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
M. Crump (1998)
10.1016/0959-8049(95)95631-F
354 Taxol® (paclitaxel) 225 MG/M2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer (MBC)
P. Bougnoux (1995)
Activity of Taxotere (T) in Japanese patients with anthracycline-resistant metastatic breast cancer (MBC)
S Tominaga (1998)
Epirubicin (EPI) and vinorelbine (VNR): a new promising combination for primary systemic chemotherapy for breast cancer patients (PTS)
C Nisticò (1998)
10.1016/S0959-8049(97)85284-7
Phase II study of i.v navelbine (NVB) and doxorubicln (DOX) in previously untreated advanced breast cancer (ABC)
D. Vorobiof (1997)
Weekly moderate-dose paclitaxel (P) in advanced breast cancer (ABC)
R Asbury (1998)
10.1200/JCO.1993.11.7.1245
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
P. Fumoleau (1993)
XelodaTM (capecitabine): an orally available tumor-selective fluoro-pyrimidine carbamate
T Ishikawa (1997)
10.1016/S0959-8049(97)85304-X
Phase II studies of two trial regimens of topotecan as second-line single agent therapy in advanced breast cancer
D. Spaëth (1997)
Vinorelbine (NVB) activity in heavily pretreated breast cancer (BC) patients (PTS)
A Alvarez (1996)
Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review.
C. Vogel (1995)
Infusional chemotherapy for breast cancer . The Cancer Center of Boston
J Lokich (1993)
Gemcitabine (GEM) and vinorelbine (VNB) in solid tumors. Preliminary results of a phase I study
JM Rodier (1997)
10.1016/0006-2952(93)90615-4
5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo.
T. Spector (1993)
Effect of Taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3- to 24-hour infusion of high-dose Taxol
E Mamounas (1998)
10.1200/JCO.1994.12.10.2094
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
G. Gasparini (1994)
Results of a combination of Navelbine (NVB) and Fluoro-Uracil (FU) in advanced breast cancer (ABC) with a group sequential design (GSD)
V Dieras (1992)
Phase II study of vinorelbine in first and second-line treatment of advanced breast cancer, Navelbine update and new trends
J-M Extra (1991)
Activity of weekly Taxotere® (TXT) in patients with metastatic breast cancer
TM Löffler (1998)
Phase II study of vinorelbine (VNR) by 96-hour (H) continuous infusion (CI) for patients (PTS) with metastatic breast cancer (MBC)
NK Ibrahim (1998)
Gemcitabine + doxorubicin in advanced breast cancer: final results from an early phase II study
J Garcia Conde (1997)
Pathophysiology and management of docetaxel-induced fluid retention
E Pujade-Lauraine (1996)
LIPOSOMAL ANTHRACYCLINE CHEMOTHERAPY IN THE TREATMENT OF AIDS : RELATED KAPOSI'S SARCOMA
D. W. Northfelt (1997)
Multicentric phase II study with vinorelbine (VNB) and epirubicin (EPI) as first line chemotherapy in metastatic breast cancer (MBC)
D Tabiadon (1998)
Feasibility study of the combination Navelbine® (N) and paclitaxel (PCL) in advanced breast cancer (ABC)
A Jaremtchuk (1997)
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
V. Diéras (1995)
Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC): final results
L Romero Acuña (1998)
10.1200/JCO.1991.9.12.2141
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.
D. Talbot (1991)
Single-agent docetaxel as salvage treatment in anthracycline-refractory breast cancer patients
P Vici (1998)
10.1097/00001813-199512006-00009
Gemcitabine in advanced breast cancer
K. Possinger (1995)
Taxotere (T) in previously treated patients (PTS) with metastatic breast carcinoma (MBC): stratification for anthracycline resistance (AR)
AT VanOosteram (1996)
Gemzar and epirubicin (EP) in patients with metastatic breast cancer (MBC): preliminary results of a phase I study
V Delecroix (1998)
Doxil ® and oral cyclophosphamide as first - line therapy for patients with metastatic breast cancer ( MBC ) : preliminary results of a pilot trial
L Holder (1998)
10.1093/JNCI/87.15.1169
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
L. Gianni (1995)
10.1200/JCO.1988.6.9.1368
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
W. Peters (1988)
Phase I evaluation of oral tegafur.
A. Bedikian (1983)
10.1016/S0959-8049(97)89288-X
P71 Epirubicin (EPI) and vinorelbine (VNR): A new promising combination for primary systemic chemotherapy for breast cancer
C. Nisticò (1998)
Phase I/II study of vinorelbine (VRLB) in combination with 5-fluorouracil and folinic acid (FUFA) in metastatic breast cancer
F Nolè (1997)
10.1016/S0959-8049(97)85243-4
Activity of gemcltabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containlng regimens
M. Spielmann (1997)
Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere® induced fluid retention
P Ravdin (1996)
10.1016/S0959-8049(97)85244-6
Phase II study of gemcltablne in patients with metastatic breast cancer
M. Blackstein (1997)
Vinorelbine (VRL) as palliative treatment in elderly patients with metastatic breast cancer
A Buonadonna (1997)
10.1093/JNCI/83.24.1797
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
F. Holmes (1991)
10.1200/JCO.1994.12.8.1621
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
W. Wilson (1994)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedioneresistant breast cancer
PM Ravdin (1995)
Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342
E Winer (1998)
Gemcitabine: preclinical pharmacology and mechanisms of action.
W. Plunkett (1996)
Doxorubicin, docetaxel and vinorelbine (ATN) with G-CSF support in the treatment of metastatic breast cancer (MBC): a pilot study
G Deplanque (1998)
Efficacy and cardiac effects of 3-H paclitaxel (P) plus bolus doxorubicin (DOX) in women with untreated metastatic breast carcinoma
L Gianni (1996)
Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies
C Twelves (1996)
10.1038/bjc.1993.146
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
R. A'hern (1993)
A randomized phase II study of Xeloda ( capecitabine ) vs CMF as first line chemotherapy of breast cancer in women aged ≥ 55 years
J O’Shaughnessy (1998)
10.1093/JNCI/82.15.1247
Taxol: a novel investigational antimicrotubule agent.
E. Rowinsky (1990)
Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: a prospective randomized clinical trial
H Nakazato (1997)
10.1093/OXFORDJOURNALS.ANNONC.A058258
Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.
J. Schornagel (1992)
A randomized phase III study of Taxotere® (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen
S Chan (1997)
Phase III study of TLC D99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast carcinoma
L Harris (1998)
Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial
GW Sledge (1997)
Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
P. Dombernowsky (1996)
A phase I/II study of Doxil and vinorelbine in metastatic breast cancer patients
MR Ramirez (1998)
Taxotere® (TXT) versus 5-fluorouracil + Navelbine® (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) (preliminary results)
J Bonneterre (1997)
New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
F. Schmid (1985)
Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.
D. Ahmann (1974)
Pegylated Liposomal Doxorubicin: Scientific Rationale and Preclinical Pharmacology
F. J. Martin (1997)
10.1200/JCO.1995.13.10.2477
High-dose chemotherapy of breast cancer: is the question answered?
M. Kennedy (1995)
Phase II trial of paclitaxel (Taxol) as first line chemotherapy for metastatic breast cancer (MBC)
S Swain (1995)
A matrix-designed phase I dose-finding and pharmacokinetic study of the combination of XelodaTM plus TaxotereTM
L Pronk (1998)
10.5555/URI:PII:0093775492900372
The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer.
I. Judson (1992)
10.1200/JCO.1995.13.12.2886
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
V. Valero (1995)
Vinorelbine (VNR) in weekly schedule with G-CSF in patients with advanced breast cancer (ABC)
M Ranuzzi (1996)
10.1023/A:1008370704612
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
G. Krajnik (2000)
10.1093/OXFORDJOURNALS.ANNONC.A058873
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.
M. Degardin (1994)
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
J. Vermorken (1995)
Fluorouracil and highdose leucovorin in previously treated patients with metastatic breast cancer
SM Swain (1989)
Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial
D. Slamon (1998)
Efficacy and safety of HerceptinTM (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
MA Cobleigh (1998)
Low activity of paclitaxel (PT) in patients with metastatic breast cancer (MBC) resistant to anthracyclines (A)
F Cognetti (1996)
Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC)
L Romero Acuña (1997)
A phase II study of topotecan on a daily x 5 schedule as second-line single agent therapy in patients with advanced breast cancer
E Goldschmidt (1997)
Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens
M Spielmann (1997)
10.1016/0277-5379(88)90046-6
The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.
A. Howell (1988)
10.1200/JCO.1995.13.8.2056
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
J. Abrams (1995)
Doxil ® in patients with pretreated metastatic breast cancer ( MBC ) : a doseschedule finding study with pharmacokinetics
A Gabizon (1997)
10.1016/0959-8049(95)95622-D
369 Advanced breast cancer: A phase II trial with gemcitabine (GEM)
K. Possinger (1995)
Losoxantrone + paclitaxel versus paclitaxel alone as first line chemotherapy for metastatic breast cancer (MBC): final results of a phase III randomized trial
PA Kaufman (1998)
Phase I trial of sequential vinorelbine-paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy
L Weiselberg (1996)
10.1200/JCO.1997.15.4.1395
Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
R. Livingston (1997)
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
L. W. Hertel (1990)
Gemzar ® nd epirubicin ( EP ) in patients with metastatic breast cancer ( MBC ) : preliminary results of a phase I study
V Delecroix (1998)
Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA.
E. Greenspan (1963)
Biochemical effects of Navelbine on tubulin and associated proteins.
A. Fellous (1989)
10.1200/JCO.1995.13.2.314
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
B. Chevallier (1995)
10.1200/JCO.1995.13.10.2575
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
A. Seidman (1995)
Second EORTC clinical screening group phase II trial of Taxotere (docetaxel) as first-line chemotherapy in advanced breast cancer
V Dieras (1994)
10.1073/PNAS.90.23.11064
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
D. Baccanari (1993)
10.1002/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U
Paclitaxel administered by 1‐hour infusion. Preliminary results of a phase 1/11 trial comparing two schedules
J. Hainsworth (1994)
10.1200/JCO.1997.15.9.3149
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
M. Piccart (1997)
10.1016/0002-9378(57)90180-1
Diseases of the Breast
C. Haagensen (1971)
10.1159/000407948
Tegafur — a Review of Pharmacology and Toxicology
W. Brade (1983)
Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine)
R. Cn (1995)
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
S. Cao (1994)
Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.
W. Leopold (1985)
Phase II study of weekly paclitaxel (P) in recurrent breast cancer after high-dose chemotherapy (HDC)
C Sola (1998)
10.1093/OXFORDJOURNALS.ANNONC.A059019
Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy.
J. Garcia-conde (1994)
A phase II trial of vinorelbine (V) and paclitaxel (P) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline containing chemotherapy
G Gardin (1998)
A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients
J Bonneterre (1993)
The Biodistribution and Pharmacokinetics of Stealth Liposomes in Patients with Solid Tumors
S. Stewart (1997)
10.1200/JCO.1995.13.11.2722
Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.
B. Weber (1995)
10.1200/JCO.1995.13.10.2483
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
W. Bezwoda (1995)
Decreased cardiac toxicity by TLC D-99 (liposomal encapsulated doxorubicin) vs. doxorubicin in a randomized trial of metastatic breast carcinoma (MBC)
G Batist (1998)
Continuous venous infusion 5-fluororacil [CVI-FU] with weekly vinorelbine [V] in chemoresistant metastatic breast cancer [MBC]: a pilot study
N Anderson (1998)
10.1200/JCO.1996.14.6.1877
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
A. Seidman (1996)
Phase II study of Taxotere (docetaxel), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
J-M Nabholtz (1997)
Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU)
R Pazdur (1996)
Weekly high-dose paclitaxel (P) demonstrates significant activity in advanced breast cancer (BC)
W Sikov (1998)
Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere® (T)
A Riva (1997)
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
M. Martín (1997)
Paclitaxel/vinorelbine (TV) chemotherapy with concurrent G-CSF for metastatic breast cancer (MBC): phase I-II study in doxorubicin-treated patients (PTS)
GK Ellis (1998)
Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer
P Khoury (1998)
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
A. Seidman (1997)
A multicenter phase II study of escalating doses of paclitaxel in combination with a fixed dose of doxorubicin as first line chemotherapy for metastatic breast cancer
B Ojeda (1998)
10.1200/JCO.1989.7.7.890
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
S. Swain (1989)
Phase II study of gemcitabine in patients with metastatic breast cancer
M Blackstein (1997)
Combination chemotherapy in hormone resistant breast cancer
RG Cooper (1969)
10.1200/JCO.1992.10.4.657
High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.
D. Eddy (1992)
Phase I trial of DaunoXome and Taxol as first line treatment in metastatic breast cancer
E Isaksson (1998)
10.1016/S0169-5002(97)89393-2
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.
G. Krajnik (1998)
Efficacy of Taxotere (TXT) in advanced breast cancer (ABC) patients (PTS) not eligible for further anthracyclines (ANT)
L Trandafir (1996)
10.1200/JCO.1996.14.6.1858
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
J. Nabholtz (1996)
Navelbine ® ( vinorelbine tartrate ) combination chemotherapy for advanced breast cancer
CL Vogel (1995)
10.1097/00000421-199510000-00006
Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience.
S. Bruno (1995)
A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: a Southwest Oncology Group (SWOG) study
CE JrGeyer (1996)
Single agent Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC). Final results of an EORTC randomized study with crossover
T Gamucci (1998)
10.1200/JCO.1995.13.12.2879
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
P. Ravdin (1995)
Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine)
C. Rittenberg (1995)
10.1200/JCO.1993.11.7.1241
Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
T. Vandenberg (1993)
10.1200/JCO.1994.12.2.336
Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.
A. Romero (1994)
Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in patients with anthracycline-resistant metastatic breast cancer
S Culine (1998)
10.1200/JCO.1994.12.8.1527
Gemcitabine: current status of phase I and II trials.
S. Kaye (1994)
Docetaxel in advanced breast carcinoma (MBC) patients (PTS) pre-treated with anthracyclines
E Terzoli (1998)
10.1097/00001813-199506000-00001
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
M. Bissery (1995)
Phase II trial of single agent docetaxel in previously treated patients (pts) with advanced breast cancer (ABC)
DA Vorobiof (1996)
A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)
T Peretz (1995)
10.1016/0020-7292(90)91032-L
Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
WP McGuire (1989)
Cardiac function following combination therapy with Taxol® (T) and doxorubicin (A) for advanced breast cancer (ABC)
L Gianni (1998)
A phase II study of DUP 941 in advanced breast cancer (CA) patients treated with prior chemotherapy
I Smith (1993)
3-hour (hr) high-dose Taxol (T) infusion in advanced breast cancer (ABC): an NSABP Phase II study
E Mamounas (1995)
Treatment of metastatic disease.
F. Storm (1979)
Doxil ® and oral cyclophosphamide as first - line therapy for patients with metastatic breast cancer ( MBC ) : preliminary results of a pilot trial
L Holder (1998)
Tumor selectivity of XelodaTM in colorectal cancer patients
J Schüller (1997)
10.1016/0959-8049(95)95598-Z
345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)
T. Peretz (1995)
RATIONALE FOR TRIALS STUDYING PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER
M. Jahanzeb (1997)



This paper is referenced by
10.1046/j.1524-4741.2003.09602.x
Clinical Experience with Trastuzumab (Herceptin)
C. Vogel (2003)
10.1097/CAD.0b013e3282ee3af2
An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer
Y. Lin (2007)
10.1097/01.coc.0000251935.51345.10
Activity and Tolerability of a Combined Palliative Chemotherapy With Mitomycin C, Folinate, and 5-Fluorouracil in Patients With Advanced Breast Cancer After Intensive Pretreatment: A Retrospective Analysis
M. Eichbaum (2007)
10.1177/009127000004001002
20th‐Century Advances in Drug Therapy in Oncology—Part II
J. Dutcher (2000)
10.1023/A:1018774618873
Angiogenesis as a Target for Breast Cancer Therapy
D. Rayson (2004)
10.1158/1078-0432.CCR-12-3779
Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
A. V. D. van der Veldt (2013)
10.1016/S0305-7372(03)00139-7
Platinum-based chemotherapy in metastatic breast cancer: current status.
M. Decatris (2004)
10.3747/co.19.879
Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.
S. Young (2012)
Utilisation de docetaxel combine a rhumab her2 pour le traitement de cancers
C. Vogel (2000)
10.1023/B:BREA.0000004374.72658.17
Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability
A. Ballestrero (2004)
Markers for effectiveness of chemotherapy and drug resistance in breast cancer
I. F. Faneyte (2005)
10.1097/00000421-200010000-00007
Cellular Immune Profile of Patients With Advanced Cancer Before and After Taxane Treatment
A. Tong (2000)
10.2147/BCTT.S71781
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase
S. Larsén (2014)
10.3816/CBC.2010.n.009
Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents.
D. Yardley (2010)
10.1177/00912700022009620
20th‐Century Advances in Drug Therapy in Oncology—Part I
J. Dutcher (2000)
10.1007/s11095-005-2593-8
Effect of Particle Size of Nanospheres and Microspheres on the Cellular-Association and Cytotoxicity of Paclitaxel in 4T1 Cells
S. De (2005)
10.1038/s41598-018-24089-5
Author Correction: Kanglaite sensitizes colorectal cancer cells to Taxol via NF-κΒ inhibition and connexin 43 upregulation
Y. Wang (2018)
10.1200/JCO.2015.33.15_SUPPL.E12086
BP-C1 in treatment of patients with stage IV breast cancer: A randomized, double-blind, placebo-controlled multicenter study and additional open-label treatment phase.
S. Larsén (2015)
The role of chemotherapy in stage IV colorectal cancer: Focus on combinations with biologic agents and conversion therapy
L. S. Schwartzberg (2008)
10.3109/07357907.2013.877480
Comparative Effectiveness of Two Metronomic Chemotherapy Schedules—Our Experience in the Preclinical Field
M. Rico (2014)
Chapter 7 Towards prediction of efficacy of chemotherapy : a proof of concept study in lung cancer using [ 11 C ] docetaxel and positron emission tomography
A. A. M. Veldt (2012)
A P hase II Study of G em citabine M onotherapy in B reast C ancer Patients R efractory to A nthracycline and T axane
J. Park (2002)
10.1634/THEONCOLOGIST.11-6-563
Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
A. Ardavanis (2006)
10.1016/S0304-4858(01)74349-1
Tratamientos futuros del Cáncer de Mama
J. Barceló (2001)
10.1097/CAD.0000000000000371
Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
C. Zhao (2016)
10.1093/ANNONC/12.SUPPL_1.S95
Trastuzumab in the treatment of advanced breast cancer: single-center experience.
M. Mrsić (2001)
rRNA disruption: a predictive marker of response to taxane chemotherapy
Rashmi Narendrula (2014)
10.3816/CBC.2001.N.016
A review of vinorelbine in the treatment of breast cancer.
G. Domenech (2001)
10.1126/SCIENCE.287.5460.1969
Mechanism-based target identification and drug discovery in cancer research.
J. Gibbs (2000)
10.1038/s41598-017-01480-2
Kanglaite sensitizes colorectal cancer cells to Taxol via NF-κΒ inhibition and connexin 43 upregulation
Y. Wang (2017)
10.2325/JBCS.13.192
Clinical experience with docetaxel for Chinese breast cancer patients: Hematological toxicity profiles
Adrian Yip (2006)
10.1016/J.CBI.2007.03.004
Antimitotic activity of methoxyconidiol, a meroterpene isolated from an ascidian.
Annabel Simon-Levert (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar